2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the...

Descripción completa

Detalles Bibliográficos
Autores principales: Buse, John B., Wexler, Deborah J., Tsapas, Apostolos, Rossing, Peter, Mingrone, Geltrude, Mathieu, Chantal, D’Alessio, David A., Davies, Melanie J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971782/
https://www.ncbi.nlm.nih.gov/pubmed/31857443
http://dx.doi.org/10.2337/dci19-0066
_version_ 1783489781424979968
author Buse, John B.
Wexler, Deborah J.
Tsapas, Apostolos
Rossing, Peter
Mingrone, Geltrude
Mathieu, Chantal
D’Alessio, David A.
Davies, Melanie J.
author_facet Buse, John B.
Wexler, Deborah J.
Tsapas, Apostolos
Rossing, Peter
Mingrone, Geltrude
Mathieu, Chantal
D’Alessio, David A.
Davies, Melanie J.
author_sort Buse, John B.
collection PubMed
description The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA(1c) or individualized HbA(1c) target; 2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and 3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min(–1) [1.73 m](–2) or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.
format Online
Article
Text
id pubmed-6971782
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-69717822021-02-01 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Buse, John B. Wexler, Deborah J. Tsapas, Apostolos Rossing, Peter Mingrone, Geltrude Mathieu, Chantal D’Alessio, David A. Davies, Melanie J. Diabetes Care Consensus Report Update The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA(1c) or individualized HbA(1c) target; 2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and 3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min(–1) [1.73 m](–2) or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death. American Diabetes Association 2020-02 2019-12-19 /pmc/articles/PMC6971782/ /pubmed/31857443 http://dx.doi.org/10.2337/dci19-0066 Text en © 2019 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.
spellingShingle Consensus Report Update
Buse, John B.
Wexler, Deborah J.
Tsapas, Apostolos
Rossing, Peter
Mingrone, Geltrude
Mathieu, Chantal
D’Alessio, David A.
Davies, Melanie J.
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
title 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
title_full 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
title_fullStr 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
title_full_unstemmed 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
title_short 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
title_sort 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the american diabetes association (ada) and the european association for the study of diabetes (easd)
topic Consensus Report Update
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971782/
https://www.ncbi.nlm.nih.gov/pubmed/31857443
http://dx.doi.org/10.2337/dci19-0066
work_keys_str_mv AT busejohnb 2019updatetomanagementofhyperglycemiaintype2diabetes2018aconsensusreportbytheamericandiabetesassociationadaandtheeuropeanassociationforthestudyofdiabeteseasd
AT wexlerdeborahj 2019updatetomanagementofhyperglycemiaintype2diabetes2018aconsensusreportbytheamericandiabetesassociationadaandtheeuropeanassociationforthestudyofdiabeteseasd
AT tsapasapostolos 2019updatetomanagementofhyperglycemiaintype2diabetes2018aconsensusreportbytheamericandiabetesassociationadaandtheeuropeanassociationforthestudyofdiabeteseasd
AT rossingpeter 2019updatetomanagementofhyperglycemiaintype2diabetes2018aconsensusreportbytheamericandiabetesassociationadaandtheeuropeanassociationforthestudyofdiabeteseasd
AT mingronegeltrude 2019updatetomanagementofhyperglycemiaintype2diabetes2018aconsensusreportbytheamericandiabetesassociationadaandtheeuropeanassociationforthestudyofdiabeteseasd
AT mathieuchantal 2019updatetomanagementofhyperglycemiaintype2diabetes2018aconsensusreportbytheamericandiabetesassociationadaandtheeuropeanassociationforthestudyofdiabeteseasd
AT dalessiodavida 2019updatetomanagementofhyperglycemiaintype2diabetes2018aconsensusreportbytheamericandiabetesassociationadaandtheeuropeanassociationforthestudyofdiabeteseasd
AT daviesmelaniej 2019updatetomanagementofhyperglycemiaintype2diabetes2018aconsensusreportbytheamericandiabetesassociationadaandtheeuropeanassociationforthestudyofdiabeteseasd